Methods For Therapeutic Targeting Cancer Stem Cells

Patients with the brain cancer glioblastoma have about a year to live once diagnosed. Glioblastoma kills quickly as it grows aggressively and patients develop resistance to the anti-cancer drug temozolomide. Studies by a team at Virginia Tech indicate that a protein called Cx43 may hold the key to temozolomide resistance. Our researchers have found that a drug targeting Cx43 dramatically enhances the sensitivity of glioblastoma cancer cells to temozolomide, thereby providing the prospect of a novel combninatorial therapy for this deadly disease.

Patent Information:
For Information, Contact:
Grant Brewer
Senior Licensing Associate
Virginia Tech Intellectual Properties, Inc.
(540) 443-9218
Zhi Sheng
Robert Gourdie